Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Jiangxi Institute of Biological Products Days Payable?
Jiangxi Institute of Biological ProductsHKSE:06915 +1.33%23 Days Payable is 63.73 as of Dec. 2025, which is 10% below its 10-year median of 70.66. GuruFocus rates HKSE:06915 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 927 Drug Manufacturers companies, Jiangxi Institute of Biological Products ranks worse than 64.29% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangxi Institute of Biological Products Days Payable Chart
Jiangxi Institute of Biological Products Annual Data
Trend
Dec23
Dec24
Dec25
Days Payable
70.66
71.37
63.73
Jiangxi Institute of Biological Products Semi-Annual Data
Dec23
Dec24
Dec25
Days Payable
70.66
71.37
63.73
HKSE:06915 vs LLY, JNJ, ABBV: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Jiangxi Institute of Biological Products's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangxi Institute of Biological Products Days Payable vs Drug Manufacturers Industry
Jiangxi Institute of Biological Products Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangxi Institute of Biological Products (HKSE:06915) has a Days Payable of 63.73 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Jiangxi Institute of Biological Products and its competitors. This is 10% below median its historical median of 70.66. Over the past decade, Jiangxi Institute of Biological Products' Days Payable has ranged from 63.73 to 71.37. According to the industry distribution chart, Jiangxi Institute of Biological Products ranks #596 out of 927 companies in the Drug Manufacturers industry, placing it in the top 64.3%.
Is Jiangxi Institute of Biological Products' Days Payable too high?
Jiangxi Institute of Biological Products' current Days Payable of 63.73 is 10% below median its 10-year median of 70.66. Over the past 10 years, this metric has ranged from a low of 63.73 to a high of 71.37. The Drug Manufacturers industry median Days Payable is 88.13. Jiangxi Institute of Biological Products' value of 63.73 is 27.7% below this industry median. Based on the distribution chart, Jiangxi Institute of Biological Products ranks #596 out of 927 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Jiangxi Institute of Biological Products has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Jiangxi Institute of Biological Products' Days Payable compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Jiangxi Institute of Biological Products ranks #596 out of 927 companies for Days Payable. This places Jiangxi Institute of Biological Products in the lower half of its industry. The industry median Days Payable is 88.13. Jiangxi Institute of Biological Products' value of 63.73 is 27.7% below this benchmark. Historically, Jiangxi Institute of Biological Products' own Days Payable has ranged from 63.73 to 71.37 over the past decade. While the company's 10-year median is 70.66 vs. the industry median of 88.13, Jiangxi Institute of Biological Products has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.13, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangxi Institute of Biological Products's current Days Payable of 63.73 is 27.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Jiangxi Institute of Biological Products and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangxi Institute of Biological Products's current Days Payable is 63.73, which is 10% below median its own 10-year median of 70.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangxi Institute of Biological Products stock overvalued right now?
Jiangxi Institute of Biological Products (HKSE:06915) has a current Days Payable of 63.73. The current Days Payable is 63.73, which is 10% below median its 10-year median of 70.66 and 27.7% below the Drug Manufacturers industry median of 88.13. Jiangxi Institute of Biological Products' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Jiangxi Institute of Biological Products (HKSE:06915), the current Days Payable is 63.73 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jiangxi Institute of Biological Products Inc is principally engaged in the business of research and development, and production and sale of human tetanus antitoxin. It operates as the provider and exporter of Human TAT in China and an antiserum platform company. Its products include biological products containing immunoglobulins or immunoglobulin F(ab')2 fragments, which are used in medical applications such as tetanus, snakebite envenoming, and rabies treatment. The majority of the company's revenue is derived from the sale of Human Tetanus Antitoxin in the Chinese mainland.
23GF Score
Get the complete analysis for HKSE:06915
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06915 has been successfully added to your 
